Mr. Blacher joined Therapix in 2017 bringing with him more than nine years of experience in biotech-related financial management, including as aÂ CFOÂ of a NASDAQ-traded company, business development, investing and operations, as well as 14 years in capital markets.
Prior to joining Therapix, Mr. Blacher was theÂ CFOÂ for Galmed Pharmaceuticals, and earlier served as Director of Business Development at Teva Innovative Ventures, Teva Pharmaceuticals' early- and mid-stage investment and in-licensing arm. In that capacity, Mr. Blacher helped build and manage Teva's portfolio of approximately 20 equity investments in biotech entities, spanning a wide range of development stage companies from pre-clinical through PhaseÂ IIIprojects, and various therapeutic areas.
Mr. Blacher also held positions in portfolio management at Deutsche Asset Management and equity research at Morgan Stanley, as well as in mergers & acquisitions at Lehman Brothers. Mr. Blacher holds anÂ MBAÂ in Finance from Columbia Business School.